UNSPSC 51381909: Oxolamine phosphate

This classification denotes a nonsteroidal antiinflammatory drug C14H19N3O.H3O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DMG78UE3PU, chemically known as 1,2,4-oxadiazole-5-ethanamine, n,n-diethyl-3-phenyl-, phosphate (1:1), but more generally known as oxolamine phosphate, which bears US NIH Compound Identifier 6431771. European Medicines Agency schedules Oxolamine phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03577MIG.

Most nations, for tariff and trade purposes, schedule oxolamine phosphate under HS 29349990 and SITC 51579. As of Q4 2014, OXOLAMINE PHOSPHATE remains US FDA's Preferred Term for this commodity. SMILES: CCN(CC)CCC1NC(NO1)C2CCCCC2.OP(=O)(O)O.

UNSPSC 51381909 Oxolamine phosphate is a Commodity code that in recent state and local solicitations covers the procurement of pharmaceutical products and related health-supply systems — specifically naloxone, drug deactivation systems, and generic multi-source pharmaceuticals distributed through authorized wholesalers to public health agencies and government employee benefit programs. State and local issuing bodies soliciting under this code include county health departments, state health and human services commissions, and cooperative purchasing alliances that aggregate demand across multiple states and jurisdictions. The work involves purchasing finished pharmaceutical products for public health initiatives, employee health plans, and community health facilities, with vendors typically required to supply through established wholesaler networks, comply with FDA and Drug Supply Chain Security Act standards, maintain current Good Manufacturing Practice certification, and meet specific insurance and operational requirements.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, with a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capability information on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and wholesaler channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products to be distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with proposals due March 26, 2026 and contract effectiveness July 1, 2026.